APA (7th ed.) Citation

A, E., C, H., S, J., JS, H., C, H., Y, M., . . . JS, W. (2024). iVAC-XS15-CLL01: Personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens. Frontiers in oncology, 14, 1441625. https://doi.org/10.3389/fonc.2024.1441625

Chicago Style (17th ed.) Citation

A, Englisch, et al. "IVAC-XS15-CLL01: Personalized Multi-peptide Vaccination in Combination with the TLR1/2 Ligand XS15 in CLL Patients Undergoing BTK-inhibitor-based Regimens." Frontiers in Oncology 14 (2024): 1441625. https://doi.org/10.3389/fonc.2024.1441625.

MLA (9th ed.) Citation

A, Englisch, et al. "IVAC-XS15-CLL01: Personalized Multi-peptide Vaccination in Combination with the TLR1/2 Ligand XS15 in CLL Patients Undergoing BTK-inhibitor-based Regimens." Frontiers in Oncology, vol. 14, 2024, p. 1441625, https://doi.org/10.3389/fonc.2024.1441625.